The Cooper Companies, Inc. COO SPX

Q: What is the current share price of The Cooper Companies, Inc. (COO)?

As of 2026-07-14 21:23 PDT, The Cooper Companies, Inc. (COO) trades at $68.51 on NasdaqGS. Its 52-week range is $58.98 to $84.32.

Q: What is the market capitalisation of COO?

The Cooper Companies, Inc. (COO) has a market capitalisation of $13.36B on NasdaqGS.

Q: What is the P/E ratio of COO?

COO trades at a trailing price-to-earnings (P/E) ratio of 58.06. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.61.

Q: What is the return on equity (ROE) of COO?

COO has a return on equity (ROE) of 2.85%. Its return on capital employed (ROCE) is 6.05%.

Q: Is COO a good stock to buy?

This page provides a data-driven analysis of The Cooper Companies, Inc. (COO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Instruments & Supplies · United States

https://www.coopercos.com

Company Profile ↓

$68.51

-6.93% 1Y

Mkt Cap$13.36B

P/E58.06

P/B1.61

52W High$84.32

52W Low$58.98

Book Value$42.27

EPS (TTM)$1.18

Company Overview

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 11.0% per year over the last five years.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.33.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Oct 2025 Revenue of $4.09B (+5.1% YoY); net profit $374.90M.
Trailing 12 Months Year-on-year growth — revenue +7.9%, earnings -4.4%.
5-Year Trend Long-term compounding — revenue CAGR 8.3%, profit CAGR 11.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	8.35%
1 Year:	7.90%

Compounded Profit Growth

5 Years:	10.96%
1 Year:	-4.44%

Stock Price Performance

1 Year:	-6.93%
6 Months:	-17.90%
3 Months:	-4.45%
1 Month:	+1.48%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 38% of range

$58.98 $84.32

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)48.88 · Neutral

Price Performance

1M+1.48%

3M-4.45%

6M-17.90%

1Y-6.93%

Valuation vs Sector

P/E of 58.06 is above the sector median of 25.41 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Profit CAGR of 11.0% over 5 years.
Generates positive free cash flow.

CONS

Trading at a high P/E of 58.1.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

58.06

Industry PE

25.41

Forward P/E

13.70

PEG Ratio

0.68

Book Value

$42.27

Price to Book

1.61

P/S

3.13

EV/EBITDA

17.86

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

8.35%

Profit 5Y

10.96%

Revenue (YoY)

7.90%

Earnings (YoY)

-4.44%

Profitability & Returns

ROCE

6.05%

ROE

2.85%

ROA

2.52%

Profit Margin

5.57%

Op Margin

-2.87%

Gross Margin

65.55%

EPS (Latest Qtr)

$-0.40

EPS (TTM)

$1.18

Balance Sheet & Liquidity

Debt/Equity

0.33

Quick Ratio

0.53

Current Ratio

1.27

Debt

$2.73B

Total Assets

$12.48B

Current Assets

Working Capital

Ownership

Promoter Holding

0.61%

Chg in Prom Hold

FII / Inst Holding

107.04%

Chg in FII Hold

-0.08%

Financial Snapshot

Enterprise Value

$13.36B

Total Revenue (TTM)

$4.23B

EBITDA

$886.40M

Free Cash Flow

$424.28M

Operating Cash Flow

$953.00M

Shares Outstanding

195.03M

Gross Margin

65.55%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	COO The Cooper Companies, Inc. SPX	68.51	58.06	$13.36B	0.00%	6.05%	2.85%	8.35%	10.96%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jul 2015	Oct 2015	Jan 2016	Apr 2016	Jul 2016	Oct 2016	Jan 2017	Apr 2017	Jul 2017	Oct 2017	Jan 2018	Apr 2018	Jul 2018	Oct 2018	Jan 2019	Apr 2019	Jul 2019	Oct 2019	Jan 2020	Apr 2020	Jul 2020	Oct 2020	Jan 2021	Apr 2021	Jul 2021	Jan 2022	Apr 2022	Jul 2022	Jan 2023	Apr 2023	Jul 2023	Jan 2024	Apr 2024	Jul 2024	Jan 2025	Apr 2025	Jul 2025	Oct 2025	Jan 2026	Apr 2026
Revenue	-	-	-	-	-	-	-	-	-	-	590.00M	631.30M	660.00M	651.50M	628.10M	654.30M	679.40M	691.60M	646.20M	524.90M	578.20M	681.60M	680.50M	719.50M	763.40M	787.20M	829.80M	843.40M	858.50M	877.40M	930.20M	931.60M	942.60M	1.00B	964.70M	1.00B	1.06B	1.07B	1.02B	1.08B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	323.20M	368.30M	414.30M	328.90M	346.10M
Gross Profit	272.90M	253.30M	262.00M	298.50M	316.60M	296.00M	312.40M	343.90M	356.20M	353.40M	370.90M	404.50M	426.80M	430.00M	418.50M	432.60M	450.70M	455.00M	426.50M	323.50M	360.80M	424.00M	450.70M	487.10M	516.10M	518.40M	532.50M	552.10M	558.50M	582.90M	610.00M	623.80M	631.20M	663.00M	660.20M	679.10M	692.00M	650.80M	695.20M	735.40M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	494.30M	516.30M	510.40M	482.40M	766.40M
Operating Income	50.31M	-	57.40M	89.80M	102.70M	-	90.70M	117.10M	112.80M	-	90.20M	74.70M	115.60M	-	110.90M	146.90M	142.20M	-	111.10M	28.60M	72.00M	-	133.40M	143.20M	100.60M	130.80M	132.70M	140.60M	149.50M	96.30M	151.60M	153.10M	161.70M	192.50M	182.00M	184.80M	175.70M	140.40M	212.80M	-31.00M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	261.30M	272.70M	239.60M	310.10M	67.90M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24.20M	25.40M	24.40M	22.40M	20.90M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	144.50M	151.90M	116.80M	192.20M	-48.40M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	56.80M	53.60M	32.20M	61.40M	29.50M
Net Income	45.00M	36.70M	51.40M	74.10M	87.90M	60.50M	75.80M	104.90M	103.60M	88.60M	-122.50M	60.90M	100.80M	100.60M	103.20M	122.40M	120.10M	121.00M	90.50M	11.50M	55.20M	81.20M	2.10B	117.50M	615.80M	95.30M	126.60M	98.40M	84.60M	39.80M	85.30M	81.20M	88.90M	104.70M	104.30M	87.70M	98.30M	84.60M	130.80M	-77.90M
Diluted EPS	0.91	0.75	1.05	1.52	1.79	1.23	1.53	2.12	2.09	1.78	-2.50	1.23	2.03	2.02	2.07	2.45	2.40	2.42	1.82	0.23	1.12	1.64	42.31	2.36	12.37	1.91	2.55	1.98	0.43	0.20	0.43	0.41	0.44	0.52	0.52	0.44	0.49	0.43	0.66	-0.40
R&D Expense	18.30M	-	14.80M	16.70M	15.90M	-	16.30M	16.80M	17.50M	-	18.80M	20.80M	22.50M	-	21.00M	21.00M	21.50M	-	22.20M	23.80M	21.80M	-	21.40M	21.00M	24.80M	26.20M	26.30M	28.70M	31.60M	32.60M	36.50M	39.50M	38.90M	39.00M	40.70M	45.50M	44.60M	-	44.30M	42.50M

Profit & Loss (Annual)

Figures in USD.

Metric	Oct 2008	Oct 2009	Oct 2010	Oct 2011	Oct 2012	Oct 2013	Oct 2014	Oct 2015	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Revenue	1.05B	1.08B	1.16B	1.33B	1.45B	1.59B	1.72B	1.80B	1.97B	2.14B	2.53B	2.65B	2.43B	2.92B	3.31B	3.59B	3.90B	4.09B
Gross Profit	610.03M	596.49M	676.72M	804.80M	924.01M	1.03B	1.09B	1.07B	1.17B	1.37B	1.63B	1.76B	1.53B	1.96B	2.14B	2.36B	2.60B	2.68B
Operating Income	126.96M	149.86M	189.91M	227.56M	283.40M	305.94M	306.49M	236.70M	324.10M	429.10M	403.10M	546.70M	311.80M	505.80M	507.60M	533.10M	705.70M	682.90M
Net Income	63.96M	100.55M	112.80M	175.43M	248.34M	296.15M	269.86M	203.50M	273.90M	372.90M	139.90M	466.70M	238.40M	2.94B	385.80M	294.20M	392.30M	374.90M
Diluted EPS	1.42	2.21	2.43	3.63	5.05	5.96	5.51	4.14	5.59	7.52	2.81	9.33	4.81	59.16	1.94	1.48	1.96	1.87
R&D Expense	35.47M	33.30M	35.27M	43.58M	51.73M	58.83M	66.26M	69.60M	65.40M	69.20M	84.80M	86.70M	93.30M	92.70M	110.30M	137.40M	155.10M	172.20M

Balance Sheet (Annual)

Figures in USD.

Metric	Oct 2007	Oct 2008	Oct 2009	Oct 2010	Oct 2011	Oct 2012	Oct 2013	Oct 2014	Oct 2015	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Total Assets	-	-	2.55B	2.53B	2.62B	2.94B	3.14B	4.46B	4.46B	4.48B	4.86B	6.11B	6.27B	6.74B	9.61B	11.49B	11.66B	12.32B	12.39B
Total Equity	1.46B	1.42B	1.54B	1.67B	1.94B	2.19B	2.40B	2.57B	2.67B	2.70B	3.18B	3.31B	3.63B	3.82B	6.94B	7.17B	7.55B	8.08B	8.24B
Cash & Equivalents	3.23M	1.94M	3.93M	3.57M	5.17M	12.84M	77.39M	25.20M	16.40M	100.80M	88.80M	77.70M	89.00M	115.90M	95.90M	138.20M	120.80M	107.60M	110.60M
Long Term Debt	-	-	771.63M	591.98M	327.45M	348.42M	301.67M	1.28B	1.11B	1.11B	1.15B	1.99B	1.26B	1.38B	1.40B	2.35B	2.52B	2.55B	2.46B
Total Liabilities	-	-	1.01B	858.24M	687.03M	728.23M	713.77M	1.87B	1.79B	1.78B	1.68B	2.81B	2.65B	2.91B	2.66B	4.32B	4.11B	4.23B	4.16B
Current Liabilities	-	-	175.41M	199.52M	267.21M	262.55M	321.25M	442.18M	568.78M	543.20M	396.10M	536.50M	1.11B	1.00B	732.10M	1.28B	969.00M	1.02B	1.11B

Cash Flows (Annual)

Figures in USD.

Metric	Oct 2008	Oct 2009	Oct 2010	Oct 2011	Oct 2012	Oct 2013	Oct 2014	Oct 2015	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Operating Cash Flow	96.53M	223.13M	267.66M	336.28M	315.12M	415.93M	454.82M	390.90M	509.60M	593.60M	668.90M	713.20M	486.60M	738.60M	692.40M	607.50M	709.30M	796.10M
Investing Cash Flow	-128.76M	-98.64M	-106.60M	-161.68M	-238.47M	-189.92M	-1.35B	-287.90M	-418.70M	-381.30M	-1.52B	-351.30M	-364.50M	-450.30M	-1.83B	-449.00M	-764.60M	-372.90M
Financing Cash Flow	31.20M	-122.74M	-161.57M	-172.87M	-68.44M	-161.60M	842.16M	-106.70M	-1.40M	-227.90M	844.40M	-351.40M	-95.50M	-311.40M	1.19B	-173.90M	39.20M	-425.90M
Capital Expenditure	-124.89M	-93.91M	-73.76M	-103.67M	-99.78M	-178.13M	-238.06M	-243.00M	-152.60M	-127.20M	-193.60M	-292.10M	-310.40M	-214.40M	-242.00M	-392.50M	-421.20M	-362.40M
Free Cash Flow	-28.36M	129.22M	193.91M	232.62M	215.34M	237.80M	216.76M	147.90M	357.00M	466.40M	475.30M	421.10M	176.20M	524.20M	450.40M	215.00M	288.10M	433.70M
Share Buybacks	-	-	0	0	71.15M	167.33M	75.78M	67.30M	0	55.00M	0	156.10M	47.80M	24.80M	78.50M	0	0	290.10M

Ratios (Annual)

Figures in %.

Metric	Oct 2008	Oct 2009	Oct 2010	Oct 2011	Oct 2012	Oct 2013	Oct 2014	Oct 2015	Oct 2016	Oct 2017	Oct 2018	Oct 2019	Oct 2020	Oct 2021	Oct 2022	Oct 2023	Oct 2024	Oct 2025
Gross Margin %	58.2%	55.2%	58.4%	60.5%	63.9%	64.7%	63.5%	59.6%	59.6%	63.9%	64.4%	66.2%	63.1%	66.9%	64.7%	65.6%	66.6%	65.5%
Operating Margin %	12.1%	13.9%	16.4%	17.1%	19.6%	19.3%	17.8%	13.2%	16.5%	20.1%	15.9%	20.6%	12.8%	17.3%	15.3%	14.8%	18.1%	16.7%
Net Margin %	6.1%	9.3%	9.7%	13.2%	17.2%	18.7%	15.7%	11.3%	13.9%	17.4%	5.5%	17.6%	9.8%	100.8%	11.7%	8.2%	10.1%	9.2%
ROE %	4.5%	6.5%	6.8%	9.1%	11.3%	12.3%	10.5%	7.6%	10.2%	11.7%	4.2%	12.9%	6.2%	42.4%	5.4%	3.9%	4.9%	4.6%
ROCE %	-	6.3%	8.2%	9.7%	10.6%	10.9%	7.6%	6.1%	8.2%	9.6%	7.2%	10.6%	5.4%	5.7%	5.0%	5.0%	6.2%	6.1%

Shareholding Pattern

Insiders

0.61%

Institutions

107.04%

Public Float

107.70%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.52%	16.62M	$1.20B
2	Vanguard Capital Management LLC	6.52%	12.72M	$917.41M
3	T. Rowe Price Investment Management, Inc.	4.65%	9.06M	$653.51M
4	State Street Corporation	4.50%	8.77M	$632.47M
5	Vanguard Portfolio Management LLC	4.47%	8.72M	$629.07M
6	Capital World Investors	3.80%	7.41M	$534.84M
7	Browning West Lp	3.58%	6.98M	$503.43M
8	Kayne Anderson Rudnick Investment Management LLC	3.39%	6.62M	$477.26M
9	Price (T.Rowe) Associates Inc	2.77%	5.39M	$389.06M
10	Geode Capital Management, LLC	2.72%	5.31M	$383.12M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for COO

Google News ue, 14 Jul 2026

Avalanche Treasury Corp (AVAT) grants COO options on 1,100,000 shares - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQQy1Jb0RaYlIteGQtTnluWmFRSnpTOXdaSTVOUDFXZGNQWmlGOXlDMmF3bUJPUnM5WDFIcTNCWlprWjJlUVZOTGdWc3pKdjNLVDdhM1VLdXBTTDZKQTVNYW0tY0RfelNxT0tUVVM4VXhxTktidkVLT01MOE83V1BUbkRZRjlJcWN3dE14b0…

Google News ue, 30 Jun 2026

Is COO Stock Attractive as MyDay Gains Meet Asia-Pacific Pressure - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNOEh0djgzc3AxQ2tIczlxZWFoaUZfelRUOTVUZnZPMmZlOVYzRDdGQTdQNWg0aTlxQmtlc3lyWlJTVXVnc2xlaEhkMUVYbU5nV2x5MWNRaXdDRVBlNGtFRE1EcEF0bC1sRF9OY3EySU1tcWQyeHRqb0NRbzlqMThqeWZzQnByWHFEcGh4dn…

Google News ue, 14 Jul 2026

SEA (NYSE:SE) COO Gang Ye Sells 20,000 Shares of Stock - MarketBeat

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNU01mY2I1YmMzcWtSWHBIcXlfTkpxcW9yLUFJVFZuWnltX21BdlN0X1BncnBPcGpTOGx1LWxteXBFQWFYd2RoeHprbjBfVENrV3lBRUc1RDJLdDVVbjhWaEhZRGdVYnRNR0FDNWxRMWtaYTBacUJpaGtyWUJSc3lWbHRJeWs2bExaSFlod0…

Google News ue, 14 Jul 2026

(COO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQdzNGdmFReU5IS0Nza0U3aWlLWHRkS3Z2WU9HUFAxZWNGZDFBRzJaS3Y0QnYzSFlFb0djN3BucXZHZWsxc251Zk1OVTRYY0JGRkRrSEZ3Nmk2VUdfN1BRN0RoMWJJeFR4RUY2NnI3LTdQU0hyTmlaOFM1WGU3WUhWZERSNmt4TmxzUlQyWj…

Google News Mon, 13 Jul 2026

Amechi Nwachuku named COO at OmniAb with stock options and severance - TradingView

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNZTdVMkYtVG11cDBNQURXYkVTdG04d2F3c0EyRE9uSzJzTC1YazVRNVAyNHVJZHhxOXVRekdzVW9mUDhPSkQ4cmRoaDJOb28zU0VIMElud0xZZ0tFeXpXbW9zYXJaRVB1VjBSTUlqSXZHTnBCSVhjUEdCa253bW5tcTdvR1NqQUtrQ2o1WC…

Google News Fri, 10 Jul 2026

An2 therapeutics COO Joshua Eizen sells $24,802 in stock - Investing.com

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxPZmtlejVCSm9Ha1VGMG9nUUR5YUcwWkVWTnNTWXpKU2prYVhYS2ZsTVdwZ2ppWmtzOUtkR3N5R2pOVGN6Ty1pdjJlUGp1OHU4Y3gxdFNmMDlMdGJzNDlYWGQtRkhaTWd5Zm9DQzJFQ2VDSWl0d2FrcDVjMlpScXRlQ3E3WVFoRjdpcDBDVG…

COO — Frequently Asked Questions

What is the current share price of The Cooper Companies, Inc. (COO)?

As of 2026-07-14 21:23 PDT, The Cooper Companies, Inc. (COO) trades at $68.51 on NasdaqGS. Its 52-week range is $58.98 to $84.32.

What is the market capitalisation of COO?

The Cooper Companies, Inc. (COO) has a market capitalisation of $13.36B on NasdaqGS.

What is the P/E ratio of COO?

COO trades at a trailing price-to-earnings (P/E) ratio of 58.06. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.61.

What is the return on equity (ROE) of COO?

COO has a return on equity (ROE) of 2.85%. Its return on capital employed (ROCE) is 6.05%.

Is COO a good stock to buy?

This page provides a data-driven analysis of The Cooper Companies, Inc. (COO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

The Cooper Companies, Inc. COO SPX

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Avalanche Treasury Corp (AVAT) grants COO options on 1,100,000 shares - Stock Titan

Is COO Stock Attractive as MyDay Gains Meet Asia-Pacific Pressure - Yahoo Finance

SEA (NYSE:SE) COO Gang Ye Sells 20,000 Shares of Stock - MarketBeat

(COO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Amechi Nwachuku named COO at OmniAb with stock options and severance - TradingView

An2 therapeutics COO Joshua Eizen sells $24,802 in stock - Investing.com

COO — Frequently Asked Questions

What is the current share price of The Cooper Companies, Inc. (COO)?

What is the market capitalisation of COO?

What is the P/E ratio of COO?

What is the return on equity (ROE) of COO?

Is COO a good stock to buy?

Explore More